sutrobio.comSutro Biopharma, Inc. is a public biotechnology company focused on clinical stage drug discovery, de

velopment and manufacturing company. Who We Are About Sutro Leadership Leadership Team Functional Leadership Team Board of Directors Scientific Advisory Board Clinical Advisory Board Collaborations Corporate Presentation Patients Clinical Trials REFRaME-O1 Patient Resources Commitment To Patients Compassionate Use Access Science Pipeline iADCs & Antibody-Drug Conjugates XpressCF+® cGMP Facility Investors Overview News & Events Company Info Financial Info Stock Data SEC Filings Governance News News Releases Presentation & Publication Events Events Audio Replays Join Us The Way We Work Join Our Team DEIB Sustainability Internships Philanthropy Employee Engagement Contact Us Patients are Sutro’s passion and purpose. Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients. Our Sutro Story WATCH 9:47 Science designed to deliver ENDLESS OPPORTUNITY Learn More Enabling a future where more is POSSIBLE. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Explore opportunities Join us and thrive in a team that values diversity and collaboration. Learn More DEIB SUSTAINABILITY VOLUNTEER INVESTOR RESOURCES NASDAQ: STRO Stock Symbol News and Events Financial Results Stock Data Press Releases Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial – Part 2 of REFRαME-O1, the registration-directed study of luvelta for patients with platinum-resistant ovarian cancer (PROC), is open for enrollment – – Planned 50 patients in... Read More Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering SOUTH SAN FRANCISCO, Calif., April 2, 2024 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug... Read More Ipsen and Sutro Biopharma Announce Exclusive Global Licensing Agreement for an ADC Targeting Solid Tumors Ipsen and Sutro Biopharma Announce Exclusive Global Licensing Agreement for an ADC Targeting Solid Tumors » Ipsen secures exclusive global rights for development and commercialization of STRO-003, an antibody-drug conjugate, completing the final stages of pre-clinical... Read More Dedicated to our patients and changing the future of oncology Follow Follow Follow Follow Follow us on social media © 2024 Sutro Biopharma, Inc. South San Francisco, California, U.S.A. SITE MAP | PRIVACY POLICY | EMAIL ALERTS | CONTACT US | VISITOR GUIDE We are using cookies to give you the best experience on our website. You can find out more about which cookies we are using or switch them off in settings . Accept Close GDPR Cookie Settings Privacy Overview Strictly Necessary Cookies Powered by GDPR Cookie Compliance Privacy Overview This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful. Strictly Necessary Cookies Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings. Enable or Disable Cookies If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again. Enable All Save...